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Abstract
Background: We evaluated the cost-effectiveness of posaconazole compared with standard azole therapy (SAT;
fluconazole or itraconazole) for the prevention of invasive fungal infections (IFI) and the reduction of overall
mortality in high-risk neutropenic patients with acute myelogenous leukaemia (AML) or myelodysplastic syndromes
(MDS). The perspective was that of the Spanish National Health Service (NHS).
Methods: A decision-analytic model, based on a randomised phase III trial, was used to predict IFI avoided, life-
years saved (LYS), total costs, and incremental cost-effectiveness ratio (ICER; incremental cost per LYS) over patients’
lifetime horizon. Data for the analyses included life expectancy, procedures, and costs associated with IFI and the
drugs (in euros at November 2009 values) which were obtained from the published literature and opinions of an
expert committee. A probabilistic sensitivity analysis (PAS) was performed.
Results: Posaconazole was associated with fewer IFI (0.05 versus 0.11), increased LYS (2.52 versus 2.43), and
significantly lower costs excluding costs of the underlying condition (€6,121 versus €7,928) per patient relative to
SAT. There is an 85% probability that posaconazole is a cost-saving strategy compared to SAT and a 97%
probability that the ICER for posaconazole relative to SAT is below the cost per LYS threshold of €30,000 currently
accepted in Spain.
Conclusions: Posaconazole is a cost-saving prophylactic strategy (lower costs and greater efficacy) compared with
fluconazole or itraconazole in high-risk neutropenic patients.
Background
Patients with neutropenia as a result of chemotherapy
for acute myelogenous leukaemia (AML) or myelodys-
plastic syndrome (MDS) are at high risk of developing
invasive fungal infection (IFI) [1-7]. Early diagnosis and
treatment of IFI are difficult and, as such, are associated
with high mortality rates in neutropenic patients. Hence,
prophylaxis of IFI has become a commonly used strat-
egy to reduce overall morbidity-mortality rates in
patients with haematologic malignancies [8].
Posaconazole is a new-generation oral azole [9] that
has been demonstrated to be superior to standard azole
therapy (SAT; fluconazole or itraconazole) in preventing
IFI and reducing overall mortality in high-risk neutrope-
nic patients [10]. In a recent study, posaconazol was
shown not only to be as efficacious as fluconazole in the
prevention of IFI but also superior to fluconazole in the
prevention of invasive aspergilosis (proven or probable)
in haematopoietic stem cell transplant patients with
graft-versus-host disease (GHVD) [11]. As such, posaco-
nazole is recommended in major clinical guidelines
[12-15] as prophylaxis for neutropenic patients with
AML or MDS (category 1/A-I). * Correspondence: sgrau@parcdesalutmar.cat
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view, the financial sustainability of new health interven-
tions is a fundamental priority due to the limitation of
the financial resources [16]. Consequently, the authori-
ties responsible for health-care provision require that
new therapeutic or preventative alternatives bear infor-
mation regarding their efficacy, safety, therapeutic use-
fulness and efficiency (cost-effectiveness) [17]. In this
sense, the financial burden of IFI is consistently high,
essentially in high-risk neutropenic patients and those
who require a protracted stay in the intensive care unit
[18-23]. The economic impact of diagnosis and treat-
ment of IFI is related to the cost of the acquisition of
the anti-fungal agent, the extra costs of hospitalisation,
the cost of diagnostic tests, laboratory analyses and
complementary tests, the diagnosis and treatment of the
adverse effects of the treatment, the management of the
therapeutic failures, and relapses that require the admin-
istration of second-line anti-fungal agents [24,25]. Dis-
ease burden and high mortality rates oblige health
authorities to be aware of efficient anti-fungal prophy-
laxis in patients at high risk of suffering IFI such as, for
example, patients with neutropenia following intensive
chemotherapy. However, despite several studies having
shown efficacy in specific groups of neutropenic patients
at high risk of IFI [26-28], there is a relative dearth of
economic evaluations of prophylactic anti-fungal agents.
Posaconazole has been shown to be more efficacious
than SAT for the prophylaxis of AML or MDS among
high-risk neutropenic patients. However, the cost of the
drug is higher than fluconazole and itraconazole. There-
fore, the objective of this study was to evaluate the cost-
effectiveness of posaconazole compared to SAT for the
prevention of IFI in patients with AML or MDS who
are at high risk of developing an IFI as a result of che-
motherapy-induced neutropenia. The perspective was
the Spanish NHS, which is a system of universal health-
care provision for 45 million citizens. The data for the
present analyses were based on the randomised phase
III trial conducted by Cornely et al [10]. The outcomes
of the analyses would be useful not only from the Span-
ish perspective but also for those European countries
with a similar health service to that in Spain.
Methods
A decision analytic model was constructed to evaluate
the cost-effectiveness of posaconazole versus SAT in
preventing IFI in high-risk neutropenic patients. Evi-
dence of clinical effectiveness of both alternatives was
based on a randomised study [10] that compared the
efficacy and safety of posaconazole with that of SAT as
prophylaxis for patients with protracted neutropenia.
The trial was conducted following good clinical practice
guidelines and the Declaration of Helsinki of the World
Medical Association. It was published on clinicaltrials.
gov (NCT00044486) and it was approved by the institu-
tional review board or ethics committee at each partici-
pating center. The numbers of IFI avoided and the
number of life years saved (LYS) with each of the alter-
native therapies were used to measure the economical
benefits. Similarly, we assessed the total cost of treat-
ment including the costs of the prophylactic anti-fungal
drug, preparation and administration of posaconazole or
SAT, and the treatment of the IFI cases in each group.
Based on this information we calculated the incremental
cost-effectiveness ratio of the most effective strategy ver-
sus the least effective, i.e. the incremental cost for each
IFI avoided and the cost for each LYS with posaconazole
compared to fluconazole or itraconazole. Model
assumptions and parameters of resource use were
decided in consultation with an advisory group. The
perspective adopted was that of the Spanish NHS, with
costs and benefits discounted at an annual rate of 3%
after the 1
st year of treatment [29].
Decision-analytical model
Using Microsoft Excel 2003 for Windows
®, an interac-
tive economic evaluation model was developed to assess
the clinical benefits obtain e dw i t he a c ht h e r a p e u t i c
option, and to estimate the associated health costs of
patients receiving prophylaxis with posaconazole or SAT
for the prevention of IFI. The costs associated with the
prevention or treatment of the IFI that may arise in
each of the treatment groups were calculated.
The model consists of two integrated parts. The first
part is a decision tree (Figure 1) that reproduces, in the
100 days post-treatment, the clinical outcomes for the
patients treated with posaconazole or with SAT in a
clinical trial comparing both strategies [10]. The deci-
sion tree starts with a decision node that describes the
prophylaxis selection for IFI, either posaconazole or
SAT. After prophylaxis initiation, the patient can
develop IFI according to the probabilities described in
the clinical trial (Table 1). The model also takes into
account the probability of survival or death once the IFI
occurrs. The model takes into account not only the
patients who do not develop IFI but also those who sur-
vive the IFI, as well as the probability of death from
other causes not related to the IFI during the initial 100
days of prophylaxis.
The second part of the model consists of an additional
Markov model [30], which extrapolates the results of the
clinical trial and simulates the progression of the disease
over the long-term course of the patients’ life, i.e.
beyond the first 100 days of prophylaxis. The patients
who survive the initial 100 days enter into this Markov
model which, following the monthly cycles, projects the
risk of death from the underlying disease (AML or
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whether or not the patients had had an IFI [31]. In this
case, the relative survival values obtained from the lit-
erature were 0.21 for AML [32] and 0.08 for MDS [33]
or other causes (Table 1).
Clinical data
Clinical efficacy data used in the analyses were collected
from a clinical trial that compared posaconazole versus
fluconazole or itraconazole in the prevention of IFI in
high-risk patients with neutropenia [10]. This was a pro-
spective, randomised, multicenter study in which 304
patients were assigned to receive posaconazole and 298
patients SAT (fluconazole in 81% and itraconazole in 19%
of patients). The patients received 200 mg posaconazole in
oral suspension three times a day (total daily dose: 600
mg), 400 mg fluconazole in oral suspension once a day
(total daily dose: 400 mg) or 200 mg itraconazole in oral
solution twice a day (total daily dose: 400 mg). Prophylaxis
was administered with each chemotherapy cycle, and was
continued until recovery from neutropenia and complete
remission, or until occurrence of an IFI, or for up to 12
weeks post-randomisation, whichever came first. Patients
were followed-up for 100 days post-randomisation, and
for 30 days after the last dose of the study drug adminis-
tered during the last chemotherapy cycle. Proven or prob-
able IFI occurred during the treatment phase in 7 of the
304 patients (2%) in the posaconazole group and in 25 of
the 298 patients (8%) in the SAT group; absolute reduc-
tion in the posaconazole group of -6% (95%CI: -9.7 to
-2.5%; p < 0.001). During the 100-days of the post-rando-
misation period, 14 of 304 patients (4.6%) in the posacona-
zole group had a proven or probable fungal infection,
compared to 33 of the 298 patients (11%) in the SAT
group (p = 0.003) (Table 1). Two patients (1%) in the
posaconazole group had invasive aspergillosis versus 20
(7%) in the SAT group (p < 0.001). The mean (± SD) time
to IFI was 41 ± 26 days in the posaconazole group and 25
± 26 days in the SAT group. Survival was significantly
longer among patients treated with posaconazole than
among patients in the SAT group. Of the 304 patients in
the posaconazole group, 49 (16%) died during the study
IFI-related death
IFI
Death from other causes
Survive Death beyond 100 days
Posaconazole Survive
Survive
Death from other causes
No IFI Death beyond 100 days
Survive
Survive
IFI-related death
IFI
Death from other causes
Survive Death beyond 100 days Fluconazole/
Itraconazole  Survive
Survive
Death from other causes
No IFI Death beyond 100 days
Survive
Survive
M
M
M
M
Patients at risk of IFI
Figure 1 Decision-tree model of posaconazole versus SAT (standard azole treatment; fluconazole or itraconazole) for the prevention
of invasive fungal infection (IFI) among high-risk neutropenic patients. M = Markov model.
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(p = 0.048). The incidence of adverse events was similar
among both treatment groups, 52% in the posaconazole
group vs 59% in the SAT group [10]. Kaplan-Meier analy-
sis of the all-cause time-to-death at the end of the 100-day
period post-randomisation showed a significant survival
benefit in favour of posaconazole over fluconazole or itra-
conazole (p = 0.04). The data on efficacy of both therapeu-
tic options are summarised in Table 1.
Patient population
The economic evaluation was performed in patients
with neutropenia resulting from chemotherapy for AML
or MDS and who were at high risk of developing an IFI.
The patient population studied correspond to the
patients at baseline in the study by Cornely et al [10].
Cost estimation
To determine the costs and benefits of the treatments
under comparison, the perspective used was that of the
Spanish NHS and, as such, only the following direct
health costs were considered (Table 2).
￿ Costs of the prophylactic treatment used. The cost
of the pharmaceutical preparation (exfactory price)
was obtained from the medication database of the
General Spanish Council of Pharmacists [34]. The
model used the values of daily dosage and treatment
duration of posaconazole, fluconazole or itraconazole
as established in the clinical trial by Cornerly et al
[10].
￿ Cost of preparation, administration and monitoring
the anti-fungal treatment. Nurse time cost of 15, 5
and 10 min for the preparation of posaconazole, flu-
conazole and itraconazole, respectively, and the costs
of the three drugs requiring hepatic function moni-
toring twice a week over the period of prophylaxis.
The unit costs of these resources were obtained
from the SOIKOS database [35] and updated to
values in euros of November 2009.
￿ Cost of IFI management. The cost per IFI of
€67,984 was considered for either treatment option.
This value was obtained from the 2005 update of
the cost of IFI in an economic evaluation of vorico-
nazol versus conventional amphotericin B in the
treatment of invasive aspergillosis in Spain [36]. The
direct costs of the drug treatment, anti-fungal medi-
cation, hospitalisation and laboratory tests were
included in this evaluation.
The model did not include the cost of the adverse
events nor the cost of management of the underlying
disease (AML or MDS) since these costs would be com-
mon and similar to both treatment groups. All the costs
are expressed in terms of euros at November 2009
values.
Table 1 Clinical data parameters used in the model; base-case and sensitivity analysis
Sensitivity analysis
Base-case estimate Deterministic Probabilistic
Reference Reference Distribution SD
Within first 100 days of prophylaxis
Probability of an invasive fungal infection (IFI)
Posaconazole 0.05 Cornely[10] 0.0344 -0.0573 Assumption Beta 0.0120
SAT 0.11 Cornely[10] 0.0825 -0.1375 Assumption Beta 0.0181
Probability of an IFI-related death
Posaconazole 0.36 Cornely[10] 0.2678 -0.4464 Assumption Beta 0.1247
SAT 0.48 Cornely[10] 0.3636-0.6060 Assumption Beta 0.0857
Probability of death from other causes (non IFI-related)
Posaconazole 0.16 Cornely[10] 0.1185-0.1975 Assumption Beta 0.0148
SAT 0.16 Cornely[10] 0.1185-0.1975 Assumption Beta 0.0148
After first 100 days of prophylaxis
Relative survival associated with acute myelogenous leukaemia (AML)
IFI 0.21 NCI[32] 0.16-0.26 Assumption Gamma 0.000
No IFI 0.21 NCI[32] 0.16-0.26 Assumption Gamma 0.000
Relative survival associated with myelodysplastic syndrome (MDS)
IFI 0.08 Kantarjian[33] 0.06-0.10 Assumption Gamma 0.000
No IFI 0.08 Kantarjian[33] 0.06-0.10 Assumption Gamma 0.000
SAT standard azole treatment (fluconazole 81% patients or itraconazole 19% patients) SD standard deviation
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time of the patient. Hence, for each prophylactic alter-
native we calculated the number of IFI avoided in 100
days, and the number of LYS over the long-term of
the patient’s life. Similarly, we obtained the total cost
for each treatment group including the costs of the
prophylaxis (drug, preparation and administration) and
of the treatment of the IFI that may arise. From these
results we calculated the incremental cost per IFI
avoided, and the incremental costs for each LYS with
the more effective treatment (in the present case posa-
conazole), compared to the less effective SAT (flucona-
zole or itraconazole).
If the result of the modelling indicated that one of the
therapeutic options was more efficacious (less IFI or
greater number of LYS) and, in turn, had a lower total
cost compared to the other option, this would establish
therapeutic dominance. If, as well, a saving is produced
relative to the alternative option, then it would be unne-
cessary to calculate the incremental cost-effectiveness
ratio [37]. If, on the other hand, one of the options eval-
uated was more efficacious but more costly than the
alternative, the incremental cost-effective ratio is calcu-
lated relative to the less costly alternative. In the analysis
we considered that one of the strategies is efficient if the
cost per LYS is less than the threshold of efficiency cur-
rently accepted in Spain, and which has been established
at < €30,000 euros per LYS [38].
Sensitivity analysis
We performed a deterministic univariate sensitivity ana-
lysis with the objective of assessing the robustness of the
model, and the consistency of the assumptions used in
the model. The parameters modified were those that
were most relevant in the model or those with the great-
est uncertainty. These were the efficacy of prophylaxis,
the risk of death from IFI, and the cost of treatment of
the IFI with a value of 75% or 125% of the value used in
the base case estimations, except for the probability of
experiencing an IFI that a wider range was considered
(Tables 1 and 2). Further, a sensitivity analysis was per-
formed applying a discount rate of 0% and 5% to the
costs and the outcomes [29].
A multivariate probabilistic sensitivity analysis (PSA)
was also performed using 1,000 second-order Monte
Carlo simulations. The assumptions of the model were
randomly modified based on probability functions
described in Tables 1 and 2.
Results
Base case analysis
I nt h eb a s ec a s eo v e rt h e1 0 0f i r s td a y so fp r o p h y l a x i s ,
the IFI per patient in the SAT group was 0.11 versus
0.05 in the posaconazole group (Table 3), i.e. posacona-
zole avoided a mean of 0.06 IFI per patient.
In the projection of progression of the disease over the
life-term of the patient, the treatment with posaconazole
achieved better clinical results, increasing the life
Table 2 Unitary costs* and treatment duration parameters used in the model; base-case and sensitivity analysis
Base-case estimate Sensitivity analysis
Deterministic Probabilistic
Reference Reference Distribution SD
Total treatment cost per day
Posaconazole 103.69 77.77 - 129.61 Assum. Gamma 0.000
Fluconazole 16.93 12.70 - 21.16 Assum. Gamma 0.000
Itraconazole 21.85 16.39 - 27.31 Assum. Gamma 0.000
Drug cost per day
Posaconazole 90.00 CGCOF[34]
Fluconazole 8.00 CGCOF[34]
Itraconazole 8.95 CGCOF[34]
Preparation, administration and monitoring treatment cost per day
Posaconazole 13.69 Gisbert[35]
Fluconazole 8.93 Gisbert[35]
Itraconazole 12.90 Gisbert[35]
Treatment duration
Posaconazole 29 Cornely[10]
Fluconazole 24 Cornely[10]
Itraconazole 29 Cornely[10]
Cost of an invasive fungal infection (IFI)
In-patient cost 67,984 Grau[36]* 50,988 - 84,980 Assum. Gamma
*In euros at November 2009 prices
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mean increase of 2.43 years in the SAT group. As such,
posaconazole produces an increase of 0.09 in LYS
(Table 3).
The total costs of treatment in the SAT group was
€7,928 per patient (Table 3), €450 related to the prophy-
lactic drug used in avoiding IFI (drug costs, administra-
tion and monitoring) and €7,478 associated with the
costs of treatment of FI in the patients with neutropenia.
In the group of patients treated with posaconazole, the
average cost per patient was €6,121, of which €3,007 was
due to the anti-fungal treatment and €3,114 for the man-
agement of IFI. The final result was a saving of €1,807
per patient treated with posaconazole compared to the
patients who received SAT prophylaxis with fluconazole
or itraconazole.
Table 3 summarises the costs and the benefits (IFI
avoided and LYS) obtained for each treatment group. The
prophylaxis with posaconazole is the dominant strategy
compared to prophylaxis with SAT i.e. the clinical out-
comes were better and with lower overall cost.
Deterministic sensitivity analysis
The results of the univariate deterministic sensitivity ana-
lysis are summarised in Table 4. All the outcomes are con-
sistent with the base case, i.e. for all the variations of the
parameters introduced into the model; posaconazole is the
dominant strategy over that of SAT.
Probabilistic sensitivity analysis
The results of the PSA show that there is a probability
of 85% that posaconazole is a cost-saving strategy, com-
pared to SAT (Figure 2) and a probability of 97% that
the incremental cost-effectiveness ratio for posaconazole
versus SAT is below the estimated €30,000 per LYS
threshold currently accepted in Spain (Figure 3).
A final sensitivity analysis was performed, to find at
what values results changed. Only when the probability
Table 3 Results of the base case of posaconazole versus SAT in the prevention of IFI among high-risk neutropenic
patients
Strategy Total costs* IFI events LYS ICER (cost per IFI avoided) ICER (cost per LYS)
Posaconazole 6,121 0.05 2.52
SAT 7,928 0.11 2.43
Difference
† -1,807 -0.06 0.09 Dominant
‡ Dominant
‡
*In euros at November 2009 prices
†Difference between posaconazole and SAT
‡Dominant strategy: posaconazole has lower cost and higher efficacy (measured as IFI avoided and LYS) compared to SAT (standard azole treatment: fluconazole
81% patients/itraconazole 19% patients)
Table 4 Results of the deterministic sensitivity analysis of posaconazole versus SAT in the prevention of IFI among
high-risk neutropenic patients
Parameter Sensitivity analysis value ICER (cost per IFI avoided) ICER (cost per LYS)
Probability of IFI; Posaconazole 0.025 Dominant* Dominant*
0.075 Dominant* Dominant*
Probability of IFI; SAT 0.075 Dominant* Dominant*
0.15 Dominant* Dominant*
Probability of an IFI-related death; Posaconazole 0.2678 Dominant* Dominant*
0.4464 Dominant* Dominant*
Probability of an IFI-related death; SAT 0.3636 Dominant* Dominant*
0.6060 Dominant* Dominant*
Probability of death from other 0.1185 Dominant* Dominant*
causes; non IFI-related 0.1975 Dominant* Dominant*
Relative survival; AML 0.16 Dominant* Dominant*
0.26 Dominant* Dominant*
Relative survival; MDS 0.06 Dominant* Dominant*
0.10 Dominant* Dominant*
Total treatment cost per day; Posaconazole 77.77 Dominant* Dominant*
129.61 Dominant* Dominant*
Total treatment cost per day; Fluconazole 12.70 Dominant* Dominant*
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was dominant over posaconazole treatment due to lower
treatment costs. The treatment with posaconazole would
not be more cost-effective if the incremental benefit
over SAT was reduced from 6% to 2%, as the ICER
would be higher than €30,000.
Discussion
The findings from this study show that, from the per-
spective of the Spanish NHS, posaconazole is more effec-
tive than standard azoles (in the present case fluconazole
or itraconazole) in preventing proven or probable IFI.
The outcome is a reduction in overall mortality and a
longer IFI-free survival among high-risk neutropenic
patients with AML or MDS. Under most conditions in
the model, posaconazole is the dominant strategy com-
p a r e dt oS A T ,i . e .p a t i e n t sw h oa r et r e a t e dw i t hp o s a c o -
nazole have avoided a greater number of IFI with a
higher survival rate while, at the same time, have lower
total costs compared to patients receiving SAT. Determi-
nistic sensitivity analyses showed that the modification of
key parameters of the model had very little impact on the
cost-effectiveness of posaconazole and, as such, the
model is considered consistent in all the established
assumptions.
Some limitations of the study need to be taken into
account when interpreting these results. Firstly, the data
on efficacy of the two therapeutic alternatives evaluated
were obtained from a single clinical trial [10] so the dif-
ferences in frequency and distribution of fungal species
Table 4 Results of the deterministic sensitivity analysis of posaconazole versus SAT in the prevention of IFI among
high-risk neutropenic patients (Continued)
21.16 Dominant* Dominant*
Total treatment cost† per day; Itraconazole 16.39 Dominant* Dominant*
27.31 Dominant* Dominant*
Discount rate for costs and benefits 0% Dominant* Dominant*
5% Dominant* Dominant*
*Dominant strategy: posaconazole has lower cost and higher efficacy (measured as IFI avoided and LYS) compared to SAT (standard azole treatment: fluconazole/
itraconazole)
†In euros at November 2009 prices
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Figure 2 Probabilistic sensitivity analysis (PSA); incremental cost-effectiveness ratio (ICER) of posaconazole versus SAT (standard azole
treatment; fluconazole or itraconazole) in the prevention of invasive fungal infection (IFI) among high-risk neutropenic patients (ICER
threshold considered is €30,000 per life-year saved).
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r e p o r t e d .A l s o ,t h ed a t ao nr e s o u r c eu s ei nt h eI F Iw e r e
estimated from the published literature and, in a retro-
spective manner, by a panel of experts (authors of this
manuscript). However, a probabilistic sensitivity analysis
was conducted to evaluate the level of uncertainty asso-
ciated with the inputs and assumptions of the model and,
as well, to determine the interactions between the vari-
ables analysed. This analysis showed that there is an 85%
probability that posaconazole is a cost-saving strategy
compared to SAT and that the probability that the incre-
mental cost-effectiveness ratio for posaconazole versus
SAT is below the accepted threshold in Spain (currently
€30,000 per LYS) is 98%. However, with regards to exter-
nal validity required by decision makers, it would be of
considerable interest to evaluate whether these results
are transferable to other settings. There may be further
doubts regarding the benefits encountered in the clinical
trial (the data from which were used in the present
model) and whether these outcomes would apply to
patients treated in routine clinical practice. On the other
hand, the quality-of-life related to health in the outcomes
of the patients treated with posaconazole or SAT was not
taken into account, nor was the cost of the management
of adverse events. However, in the referenced clinical
trial [10], the incidence of adverse events was similar in
both treatment groups. Similarly, the costs of manage-
ment of the underlying diseases were not incorporated in
the model since these were considered to be equal in the
two alternative treatments and, consequently, would not
have an impact on the final outcomes of the analyses.
Although our results are only valid for the Spanish
National Health Care System due to the local nature
of costs, our findings are in line with previous cost-
effectiveness analyses of posaconazole in the preven-
tion of IFI among high-risk neutropenic patients with
AML or MDS, based on Cornely study [10], conducted
in other European countries and in the USA. All the
cost-effectivenes analyses followed similar methodology
and show that the incremental cost per LYS of posaco-
nazole versus SAT is below the threshold commonly
accepted in each of the countries as ceiling threshold
for determining society’s willingness to pay for a treat-
ment, even when it is a dominant strategy (cost-saving)
[28,39-43].
Conclusion
Our results suggest that prophylactic posaconazole in
neutropenic patients with acute myelogenous leukaemia
or myelodysplastic syndromes could potentially increase
patient life expectancy and reduce the overall health-
care budget.
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Figure 3 Cost-effectiveness acceptability curve; probability that posaconazole is cost-effective relative to SAT (standard azole
treatment; fluconazole or itraconazole).
Grau et al. BMC Infectious Diseases 2012, 12:83
http://www.biomedcentral.com/1471-2334/12/83
Page 8 of 10Acknowledgements
The authors thank Amy O’Sullivan of i3Innovus for programming the model.
This study received an unconditional grant from Schering-Plough. Authors
had independence from the funding body in study design, analysis and
interpretation of the data, report writing and submission for publication.
Author details
1Hospital del Mar, Barcelona, Spain.
2Hospital de la Princesa, Madrid, Spain.
3Health Economics and Outcomes Research IMS Health, Madrid, Spain.
4Hospital Universitario La Fe, Valencia, Spain.
5Hospital Clinic, Barcelona,
Spain.
6Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain.
Authors’ contributions
SG, RC, MAS, EC and IJ participated in data interpretation and writing the
manuscript. MAC participated in study concept, designing the study, data
interpretation and writing the manuscript. FJS participated in study concept.
All the authors read and approved the final manuscript.
Competing interests
R. de la Cámara, E. Carreras, M.A. Sanz and I. Jarque: have received honoraria
for speaking at symposia organised on behalf of Pfizer, Merck Sharp &
Dohme (MSD), Schering-Plough and Gilead Science and has sat on advisory
boards for antifungal agents on behalf of MSD, Schering-Plough, Pfizer and
Gilead; S. Grau: has received honoraria for speaking at symposia organised
on behalf of Pfizer; M.A. Casado has served as an external consultant for
Schering-Plough S.A; F.J. Sabater was an employee of Schering-Plough at the
moment of manuscript first submission.
Received: 12 September 2011 Accepted: 3 April 2012
Published: 3 April 2012
References
1. Ascioglu S, de Pauw BE, Meis JF: Prophylaxis and treatmentof fungal
infections associated with haematological malignancies. Int J Antimicrob
Agents 2000, 15:159-168.
2. Bow EJ, Laverdière M, Lussier N, Rotstein C, Cheang MS, Ioannou S:
Antifungal prophylaxis for severely neutropenic chemotherapy
recipients: a meta-analysis of randomized controlled clinical trials. Cancer
2002, 94:3230-3246.
3. Robenshtok E, Gafter-Gvili A, Goldberg E, Weinberger M, Yeshurun M,
Leibovici L, et al: Antifungal prophylaxis in cancer patients after
chemotherapy or hematopoietic stem-cell transplantation: systematic
review and meta-analysis. J Clin Oncol 2007, 25:5471-5489.
4. Maertens J, Buve K, Anaissie E: Broad-spectrum antifungal prophylaxis in
patients with cancer at high risk for invasive mold infections:
counterpoint. J Natl Compr Canc Netw 2008, 6:183-189.
5. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, et al:
Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis
2003, 37:1172-1177.
6. Enoch DA, Ludlam HA, Brown NM: Invasive fungal infections: a review of
epidemiology and management options. J Med Microbiol 2006,
55:809-818.
7. Zaoutis TE, Heydon K, Chu JH, Walsh TJ, Steinbach WJ: Epidemiology,
outcomes, and costs of invasive aspergillosis in immunocompromised
children in the United States, 2000. Pediatrics 2006, 117:e711-e716.
8. Safdar A: Difficulties with fungal infections in acute myelogenous
leukemia patients: immune enhancement strategies. Oncologist 2007,
12(suppl 2):2-6.
9. Frampton JE, Scott LJ: Posaconazole: a review of its use in the
prophylaxis of invasive fungal infections. Drugs 2008, 68:993-1016.
10. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al:
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with
neutropenia. N Engl J Med 2007, 356:348-359.
11. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A,
Tarantolo SR, et al: Posaconazole or fluconazole for prophylaxis in severe
graft-versus-host disease. N Engl J Med 2007, 356:335-347.
12. Maertens JA, Frere P, Lass-Florl C, Heinz W, Cornely OA: Primary antifungal
prophylaxis in leukaemia patients. Eur J Cancer Suppl 2007, 5:43-48.
13. Meunier F, Lukan C: The First European Conference on Infections in
Leukaemia-ECIL1: a current perspective. Eur J Cancer 2008, 44:2112-2117.
14. National Comprehensive Cancer Network: Prevention and treatment of
cancer-related infection. NCCN Clinical Practice Guidelines in Oncology.
[http://www.nccn.org/professionals/physician_gls/PDF/infections.pdf],
V.1.2008.
15. Walsh T, Anaissie E, Denning D, Herbrecht R, Kontoyiannis D, Marr K, et al:
Treatment of aspergillosis: clinical practice guidelines of the Infectious
Diseases Society of America. Clin Infectious Dis 2008, 46:327-360.
16. Ess SM, Schneeweiss S, Szucs TD: European healthcare policies for
controlling drug expenditure. Pharmaco Econ 2003, 21:89-103.
17. Chambers M, Hutton J, Nuitjen M: Budget impact analysis for health
technology appraisal: development and application within the NICE
appraisal process. J Clin Excellence 2002, 4:203-206.
18. Slavin M, Fastenau J, Sukarom I, Mavros P, Crowley S, Gerth WC: Burden of
hospitalization of patients with Candida and Aspergillus infections in
Australia. Int J Infect Dis 2004, 8:111-120.
19. Olaechea PM, Palomar M, León-Gil C, Alvarez-Lerma F, Jordá R, Nolla-Salas J,
et al: EPCAN Study Group. Economic impact of Candida colonization and
Candida infection in the critically ill patient. Eur J Clin Microbiol Infect Dis
2004, 23:323-330.
20. Alvarez-Lerma F, Nicolás-Arfelis JM, Rodríguez-Borregán JC, Díaz-Regañón J,
Sa-Borges M, García-López F, et al: Clinical use and tolerability of
voriconazole in the treatment of fungal infections in critically ill patients.
J Chemother 2005, 17:417-427.
21. Wenzel R, Del Favero A, Kibbler C, Rogers T, Rotstein C, Mauskopf J, et al:
Economic evaluation of voriconazole compared with conventional
amphotericin B for the primary treatment of aspergillosis in
immunocompromised patients. J Antimicrob Chemother 2005, 55:352-361.
22. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH: Mortality,
morbidity, and cost associated with febrile neutropenia in adult cancer
patients. Cancer 2006, 106:2258-2266.
23. Cagatay AA, Cosan F, Karadeniz A, Besısık SK, Ozsut H, Nalcaci M, et al: The
clinical and pharmacoeconomic analysis of invasive aspergillosis in adult
patients with haematological diseases. Mycoses 2008, 51:328-335.
24. Wingard JR, Kubilis P, Lee L, Yee G, White M, Walshe L, et al: Clinical
significance of nephrotoxicity in patients treated with amphotericin B
for suspected or proven aspergilosis. Clin Infect Dis 1999, 29:1402-1407.
25. Wingard JR, Herbrecht R, Mauskopf J, Schlamm HT, Marciniak A, Roberts CS:
Resource use and cost of treatment with voriconazole or conventional
amphotericin B for invasive aspergillosis. Transpl Infect Dis 2007,
9:182-188.
26. Penack O, Reinhold T, Thiel E, Blau IW: Cost-benefit assessment of
antifungal prophylaxis with liposomal amphotericin B in neutropenic
patients. Onkologie 2007, 30:621-626.
27. de Vries R, Daenen S, Tolley K, Glasmacher A, Prentice A, Howells S, et al:
Cost effectiveness of itraconazole in the prophylaxis of invasive fungal
infections. PharmacoEconomics 2008, 26:75-90.
28. Stam WB, O’Sullivan AK, Rijnders B, Lugtenburg E, Span LF, Janssen JJ, et al:
Economic evaluation of posaconazole versus standard azole prophylaxis
in high risk neutropenic patients in the Netherlands. Eur J Haematol
2008, 81:467-474.
29. López-Bastida J, Oliva J, Antoñanzas F, García-Altés A, Gisbert R, Mar J, Puig-
Junoy J: Spanish recommendations on economic evaluation of health
technologies. Eur J Health Econ 2010, 11:513-520.
30. Briggs A, Sculpher M: An introduction to Markov modelling for economic
evaluation. Pharmaco Econ 1998, 13:397-409.
31. Spanish National Statics Institute. [http://www.ine.es].
32. National Cancer Institute (NCI): SEER Cancer Statistics Review 1975-2003.
Age-adjusted SEER incidence and US death rates and 5-year relative
survival rates. 2006.
33. Kantarjian H, Beran M, Cortes J, O’Brien S, Giles F, Pierce S, et al: Long-term
follow-up results of the combination of topotecan and cytarabine and
other intensive chemotherapy regimens in myelodysplastic syndrome.
Cancer 2006, 106:1099-1109.
34. General Spanish Council of Pharmacists. BOT database of pharmaceutical
prices [http://www.botplusweb.portalfarma.com].
35. Gisbert R, Brosa M, [CD-ROM database]: Healthcare Reference Costs.
Barcelona: Centre d’Estudis en Economı’a de la Salut i de la Política Social;
2005, SOIKOS Version 2.2.
36. Grau Cerrato S, Mateu de Antonio J, Soto Alvarez J, Muñoz Jareño MA,
Salas Sánchez E, Marín-Casino M, et al: Economic evaluation of
Grau et al. BMC Infectious Diseases 2012, 12:83
http://www.biomedcentral.com/1471-2334/12/83
Page 9 of 10voriconazole versus amphotericin B in the treatment of invasive
aspergilosis. Farm Hosp 2005, 29:5-10.
37. Gold MR, Siegel JE, Russell LB, Weinstein MC: Cost-effectiveness in Health and
Medicine New York: Oxford University Press; 1996.
38. Sacristán JA, Oliva J, Del Llano J, Prieto L, Pinto JL: What is an efficient
health technology in Spain? Gac Sanit 2002, 16:334-343.
39. Collins CD, Ellis JJ, Kaul DR: Comparative cost-effectiveness of
posaconazole versus fluconazole or itraconazole prophylaxis in patients
with prolonged neutropenia. Am J Health-Syst Pharm 2008, 65:2237-2243.
40. O’Sullivan AK, Pandya A, Papadopoulos G, Thompson D, Langston A,
Perfect J, Weinstein MC: Cost-effectiveness of posaconazole versus
fluconazole or itraconazole in the prevention of invasive fungal
infections among neutropenic patients in the United States. Value Health
2009, 12:666-673.
41. Greiner RA, Meier Y, Papadopoulos G, O’Sullivan AK, Imhof A: Cost-
effectiveness of posaconazole compared with standard azole therapy for
prevention of invasive fungal infections in patients at high risk in
Switzerland. Oncology 2010, 78:172-180.
42. Tahami AA, O’Sullivan AK, Papadopoulos G: Posaconazole versus standard
azole therapy in the prophylaxis against invasive fungal infections
among high-risk neutropenic patients in Canada: a cost-effectiveness
analysis. 18th European Congress of Clinical Microbiology and Infectious
Diseases. European Society of Clinical Microbiology and Infectious Diseases
(ESCMID). Barcelona, Spain, 19-22 April 2008. Abstract number: P1029 .
43. Thalheimer M, Cornely OA, Hoppe-Tichy T, Schuler U, Knoth H, Kiehl M,
et al: Pharmaco-economic analyis of posaconazole versus standard azole
prophylaxis in high-risk neutropenic AML/MDS patients in Germany.
18th European Congress of Clinical Microbiology and Infectious Diseases.
European Society of Clinical Microbiology and Infectious Diseases (ESCMID).
Barcelona, Spain, 19-22 April 2008. Abstract number: P1031 .
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2334/12/83/prepub
doi:10.1186/1471-2334-12-83
Cite this article as: Grau et al.: Cost-effectiveness of posaconazole versus
fluconazole or itraconazole in the prevention of invasive fungal
infections among high-risk neutropenic patients in Spain. BMC Infectious
Diseases 2012 12:83.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Grau et al. BMC Infectious Diseases 2012, 12:83
http://www.biomedcentral.com/1471-2334/12/83
Page 10 of 10